Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070300
Filing Date
2025-05-13
Accepted
2025-05-13 16:05:32
Documents
70
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q igms-20250331.htm   iXBRL 10-Q 2508492
2 EX-31.1 igms-ex31_1.htm EX-31.1 16183
3 EX-31.2 igms-ex31_2.htm EX-31.2 14877
4 EX-32.1 igms-ex32_1.htm EX-32.1 9575
5 EX-32.2 igms-ex32_2.htm EX-32.2 9544
  Complete submission text file 0000950170-25-070300.txt   9665761

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT igms-20250331.xsd EX-101.SCH 1373883
73 EXTRACTED XBRL INSTANCE DOCUMENT igms-20250331_htm.xml XML 1709192
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

EIN.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39045 | Film No.: 25939967
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)